User:Enrospv/Nanatinostat

Nanatinostat

Clinical data
Trade names	Nstat
Other names	CHR-3996, VRx-3996
Drug class	HDAC inhibitor
Identifiers
IUPAC name 2-[(1S,5R)-6-[(6-fluoroquinolin-2-yl)methylamino]-3-azabicyclo[3.1.0]hexan-3-yl]-N-hydroxypyrimidine-5-carboxamide
CAS Number	1256448-47-1
PubChem CID	49857317
DrugBank	DB15419
ChemSpider	26632319
UNII	YTL7A418KQ
ChEMBL	ChEMBLCHEMBL1801250
Chemical and physical data
Formula	C20H19FN6O2
Molar mass	394.41 g·mol−1
3D model (JSmol)	Interactive image
SMILES C1C2C(C2NCC3=NC4=C(C=C3)C=C(C=C4)F)CN1C5=NC=C(C=N5)C(=O)NO
InChI InChI=InChI=1S/C20H19FN6O2/c21-13-2-4-17-11(5-13)1-3-14(25-17)8-22-18-15-9-27(10-16(15)18)20-23-6-12(7-24-20)19(28)26-29/h1-7,15-16,18,22,29H,8-10H2,(H,26,28)/t15-,16+,18+ Key:QRGHOAATPOLDPF-BYICEURKSA-N

Nanatinostat is an orally bioavailable HDAC inhibitor developed by Viracta Therapeutics for the treatement of Epstein–Barr virus-associated lymphoproliferative diseases in combination with valganciclovir.

Side effects include cytopenias such as thrombocytopenia, neutropenia and lymphopenia and long QT syndrome at high doses.